VEGFA and Abnormal retinal morphology: The anti-VEGF treatments ranibizumab (Lucentis®) and aflibercept (Eyelea®) were approved in Germany for the treatment of retinal diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), branch retinal vein occlusions (BRVO), and central retinal vein occlusions (CRVO).